This study will determine the initial efficacy of phendimetrazine as a pharmacotherapy for cocaine dependence. A rigorous, inpatient human laboratory study will be conducted in which the subjective, physiological and reinforcing effects of cocaine are evaluated during maintenance on placebo and phendimetrazine.

Start Date01 Aug 2015

Sponsor / Collaborator

University of Kentucky

[+1]

100 Clinical Results associated with Phendimetrazine Tartrate

100 Translational Medicine associated with Phendimetrazine Tartrate

100 Patents (Medical) associated with Phendimetrazine Tartrate

333

Literatures (Medical) associated with Phendimetrazine Tartrate

01 Jan 2024·Yonsei Medical Journal

Analysis of Prescription Trends for Narcotic Appetite Suppressants: Utilizing the Narcotics Information Management System

Article

Author: Oh, Kyung Sun ; Han, Euna

PURPOSEThe aim of this study was to systematically analyze the prescription trends of medical narcotic appetite suppressants in South Korea.MATERIALS AND METHODSData was extracted from the Narcotics Information Management System dataset from 2020, which encompasses nationwide information concerning the use of medical narcotics. The selected variables for this study included the types of prescribed medical narcotic appetite suppressants, gender, age, region, and the category of medical institution. Regional prescription trends were compared by utilizing the defined daily doses for statistical purposes (S-DDD).RESULTSThe prescription of medical narcotic appetite suppressants was predominantly for females (94%), with the highest prescription rates identified in the 30-40 age group. The majority of these prescriptions were dispensed by clinics. Within the category of narcotic appetite suppressants, phentermine and phendimetrazine were found to have higher prescription rates. Notably, the region of Daegu recorded the highest S-DDD value (12.66) in phentermine consumption.CONCLUSIONOur findings underscore the need for governmental policy and guidance to address the risks linked to the long-term use of medical narcotic appetite suppressants. This is crucial to ensure their safe and efficacious prescription and administration.

01 Dec 2023·Biomedicine & Pharmacotherapy

Abused drug-induced intracranial self-stimulation is correlated with the alteration of dopamine transporter availability in the medial prefrontal cortex and nucleus accumbens of mice

Article

Author: Hong, Eunchong ; Gu, Sun Mi ; Hong, Jin Tae ; Yun, Jaesuk ; Zhang, Yong-Qing ; Yu, Eunhye ; Lee, Jaejun ; Min, Hyun Kyu ; Lee, Dohyun ; Yoon, Seong Shoon

Intracranial self-stimulation (ICSS) of the medial forebrain bundle in mice is an experimental model use to assess the relative potential of reward-seeking behaviors. Here, we used the ICSS model to evaluate the abuse potential of 18 abused drugs: 3-Fluoroethamphetamine (3-FEA); methylphenidate; cocaine; dextroamphetamine; alpha-Pyrrolidinobutyrophenone (α-PBT); 4'-Fluoro-4-methylaminorex (4-FPO); methamphetamine; larocaine; phentermine; paramethoxymethamphetamine (PMMA); phendimetrazine; N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB-48); Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (CB-13); 4-Ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-210); Naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018); N-(ortho-methoxybenzyl)-4-ethylamphetamine (4-EA-NBOMe); N-[(2-Methoxyphenyl)methyl]-N-methyl-1-(4-methylphenyl)propan-2-amine (4-MMA-NBOMe); and 1-[1-(4-methoxyphenyl)cyclohexyl]piperidine (4-MeO-PCP). We determined dopamine transporter (DAT) availability in the medial prefrontal cortex (mPFC), striatum, and nucleus accumbens (NAc) after drug treatment. DAT availability in the mPFC and NAc significantly correlated with the ICSS threshold after drug treatment. Extracellular dopamine and calcium levels in PC-12 cells were measured following drug treatment. After drug treatment, Spearman rank and Pearson correlation analyses showed a significant difference between the extracellular dopamine level and the ICSS threshold. After drug treatment, Spearman rank correlation analysis showed a significant correlation between Ca²⁺ signaling and the ICSS threshold. A positive correlation exists between the ICSS threshold and DAT availability in the mPFC and NAc provoked by abused drugs. The relative potential of drug-induced reward-seeking behavior may be related to DAT availability-mediated extracellular dopamine levels in the mPFC and NAc.

23 Nov 2023·European Journal of Psychotraumatology

Examining MEmory Training for Recovery-Adolescent among Afghan adolescent boys: a pilot randomised controlled trial

Article

Author: Muradi, Nasima ; Sarwary, Sayed Ali Akbar ; Earnest, Arul ; Masha, Sakina ; Ahmadi, Sumia ; Ahmadi, Sayed Jafar ; Jobson, Laura ; Sarwary, Sayed Abbas ; Samim, Nasrat Ullah ; McAvoy, Daniel ; Shahinzada, Shamila ; Musavi, Zeinab

Objective: To conduct a pilot randomised controlled trial examining the feasibility, acceptability and efficacy of MEmory Training for Recovery-Adolescent (METRA) in improving psychological symptoms among Afghan adolescent boys following a terrorist attack.Method: A pilot randomised controlled trial compared METRA to a Control Group, with a three-month follow-up. The study occurred in Kabul (June-November 2022). Fifty-eight boys aged 14-19 years (Mage = 16.70, SD = 1.26) with heightened posttraumatic stress disorder (PTSD) symptoms were recruited through a local school that had recently experienced a terrorist attack. Participants were randomised 1:1 to receive METRA (n = 28) (10 session group-intervention) or Control (n = 30) (10 group-sessions of study skills). Primary outcomes were self-reported PTSD symptoms at post-intervention. Secondary outcomes included self-reported anxiety, depression, Afghan-cultural distress symptoms and psychiatric difficulties.Results: There were challenges in youth participation related to security and competing education demands. For those who did complete METRA, METRA was deemed feasible and acceptable. Following the intent-to-treat principle, linear mixed effects models found at posttreatment the METRA group had a 20.89-point (95%CI -30.66, -11.11) decrease in PTSD symptoms, while the Control Group had a 1.42-point (95%CI -8.11, 5.27) decrease, with the group over time interaction being significant (p < .001). METRA participants had significantly greater reductions in depression, anxiety, Afghan-cultural distress symptoms and psychiatric difficulties than did Controls. All gains were maintained at three-month follow-up.Conclusions: With some modifications, METRA appears a feasible intervention for adolescent boys in humanitarian contexts in the aftermath of a terrorist attack.

News (Medical) associated with Phendimetrazine Tartrate

02 Oct 2024

·www.globenewswire.com

OrganOx metra® System Approved for Liver Transplantation in Canada

2025 commercial launch planned to expand access to this platform technologyOXFORD, England and MADISON, N.J., Oct. 02, 2024 (GLOBE NEWSWIRE) -- OrganOx Ltd, a world-leading organ medical technology company, today announced Health Canada has approved the OrganOx metra® System for use during liver transplantation. The OrganOx metra® System is currently commercially available for liver transplantation in the U.S., the U.K., and the European Union. The company plans to commercially launch the system in Canada in 2025. The OrganOx metra® System utilizes normothermic machine perfusion, or NMP, to circulate oxygenated blood, medications, and nutrients to donated organs at normal body temperature and near physiological conditions. This innovative technology extends organ preservation time, allows pre-transplant clinical assessment of organ viability and can dramatically improve operational logistics for both transplant teams and patients.1 “We are thrilled to receive this authorization in Canada, further advancing our vision to improve clinical outcomes for liver transplant patients around the globe,” said Craig Marshall, CEO of OrganOx. “In the coming months we look forward to introducing the metra® to transplant centers across Canada.” The performance of the metra® system has been evaluated across several clinical trials including the Consortium for Organ Preservation in Europe (COPE) European Trial, the first randomized trial to assess machine perfusion versus static cold storage in liver transplantation. Compared with static cold storage, the OrganOx metra® achieved a 50% lower level of graft injury despite a 54% longer mean preservation time.2 About OrganOxOrganOx is a commercial stage organ technology company with a focus on the preservation of isolated organs, spun out of the University of Oxford in 2008. The company’s first product, the OrganOx metra® normothermic machine perfusion (NMP) system for the liver, has been used to support more than 4,000 liver transplant operations globally, optimizing the use of donated organs by enabling assessment of the quality of livers as well as longer preservation durations. Other applications, including in kidney transplantation, are in development. Learn more at www.organox.com. About OrganOx metra®OrganOx metra® is a fully automated NMP device that enables continuous monitoring and evaluation of the liver, empowering surgeons to make evidence-based decisions on whether to transplant a donor organ and enabling viability testing.1 metra® is commercially available in UK (UKCA: 772261), European Union (CE Mark: MDR 772263 and MDR 772678) and the United States (FDA Approved: P200035). ContactsInvestor Relations:Steve DeitschChief Financial Officer, OrganOxinvestorrelations@organox.com Media:Emma YangHealth+Commerceemma@healthandcommerce.com References: Watson, C.J.E, Gaurav, R., Fear, C. et al. Predicting Early Allograft Function After Normothermic Machine Perfusion. Transplantation 106(12): 2391–2398 (2022) https://doi.org/10.1097/TP.0000000000004263Nasralla, D., Coussios, C.C., Mergental, H. et al. A randomized trial of normothermic preservation in liver transplantation. Nature 557, 50–56 (2018). https://doi.org/10.1038/s41586-018-0047-9

Clinical Study

100 Deals associated with Phendimetrazine Tartrate

External Link

KEGG	Wiki	ATC	Drug Bank
D02080	Phendimetrazine Tartrate	A08A	DB01579

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	US	Virtus Pharmaceuticals LLC	16 Apr 1979

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis